A researcher in a lab looking at a tablet.

Category: Research

  • Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC

    Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC

    Read More

  • Gilteritinib overcomes Lorlatinib resistance in ALK-rearranged cancer

    by Mizuta et al. (Japan) A common problem we face is that cancer becomes resistant to our TKIs (Crizotinib, Brigatinib, Alectinib, Ceritinib, and Lorlatinib) over time. There are two known […]

    Read More

  • So what about immunotherapy?

    The hot phrase in cancer treatment is immunotherapy right now. What does it mean for ALK+patients?  Sometimes, you hear that immunotherapy does not work? But why are we trying to […]

    Read More

  • ,

    Dr. Vincent Lam at ALKtALK

    Director, Esophageal Cancer Research Program, Assistant Professor of Oncology Expertise: Esophageal Cancer & Lung cancer  Dr Lam: I am so excited to join your conversation tonight on a Sunday evening.  […]

    Read More

  • ,

    Dr. Benjamin Levy & NPC Rasheda Persinger join ALKtALK

    BENJAMIN PHILLIP LEVY, MD, Clinical Director of Medical Oncology Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital Associate Professor of Oncology RASHEDA PERSINGER, Nurse Practitioner Johns Hopkins Sidney […]

    Read More

  • The cover to Translational Lung Cancer Research.

    ALK Genetics 101

    About two years ago (before Dr. Ken Culver was hired as ALK Positive Inc Director of Research and Clinical Affairs, and Colin Barton was still leading the ALK Positive Inc Medical Committee), Colin received an email from Dr. Justin Gainor and Dr. Jessica Lin from Massachusetts General Hospital, inviting ALK Positive Inc to contribute to…

    Read More

  • Real World Data in Medical Research

    What is real world data vs. on-paper data?  Scientists create experiments in laboratories and present the best data they can in published papers for everyone to share.  That’s paper data.  […]

    Read More

  • ,

    Dr. Justin Gainor & Dr. Aaron Hata join ALKtALK

    Dr. Justin Gainor, MD Director of Center for Thoracic Cancers & Director of Targeted Immunotherapy at Massachusetts General Hospital, Boston Assistant Professor of Medicine at Harvard Medical School “It’s great […]

    Read More

  • ,

    Dr. Mark Awad & Dr. Roberto Chiarle join ALKtALK

    Mark Awad, MD, PhD  Clinical Director, Thoracic Oncology Treatment Center Assistant Professor of Medicine, Harvard Medical School I hope everyone is safe, warm, and healthy tonight. I am the Clinical […]

    Read More

  • Ensartinib: the unknown TKI

    Ensartinib (x396) is a medicine made by Xcovery, a biotech company based in Florida. It works closely with another company called Betta Pharmaceuticals in China for many of its trials. […]

    Read More

  • ,

    Dr. Jessica Lin and Dr. Ibiayi Dagogo-Jack join ALKtALK

    Dr. Jessica Lin Attending physician, Hematology/Oncology, Massachusetts General Hospital Instructor, Medicine, Harvard Medical School Dr. Lin: I first began interested in oncology in my undergraduate years. I started out as […]

    Read More

  • Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations

    An updated review of the most current targeted therapies in NSCLC (non-small cell lung cancer) by targetable mutation. Dr. David Konig, Dr. Spasenija S. Prince, and Dr. Sacha I Rothschild […]

    Read More